Full-Time

Software Test Development Engineer 1

Posted on 8/10/2026

Deadline 8/25/26
Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

Compensation Overview

$71.6k - $119.3k/yr

Company Does Not Provide H1B Sponsorship

Virginia, USA

Remote

Remote home office; travel required 15–25%.

Bachelor's

Category
QA & Testing (1)
Required Skills
Kubernetes
Agile
Python
Airflow
Distributed Systems
NoSQL
Software Testing
BigQuery
SQL
Apache Kafka
Docker
Quality Assurance (QA)
Microservices
AWS
DevOps
Google Cloud Platform

Get referred to Dexcom

See people who can refer or advise you

Requirements
  • One to two years of hands-on experience in software development or software test development using Python or other object-oriented programming languages.
  • Experience with SQL and NoSQL databases.
  • Experience with automated test development in application programming interface testing.
  • Experience with a variety of automated testing frameworks, including Robot Framework.
  • Strong understanding of application programming interface testing, microservices, and distributed systems in cloud environments.
  • Experience with automated user-interface testing.
  • Experience working with cloud applications such as Google Cloud or Amazon Web Services.
  • Experience with containerization tools such as Docker and Kubernetes.
  • Experience with continuous integration and continuous delivery, especially using cloud-based technologies.
  • Five or more years of Agile development and test development experience.
  • Ability to collaborate cross-functionally with software development teams on testing, deployment, and reporting product performance, quality, security, and stability.
  • Ability to work independently with minimal guidance and strong verbal and written communication skills.
  • A Bachelor's degree in a technical discipline and zero to two years of related experience.
Responsibilities
  • Write automated tests and perform automated, manual, and ad hoc testing throughout the development cycle.
  • Participate in developing software requirements and design specifications.
  • Design, develop, execute, and maintain automated and manual test scripts for Dexcom continuous glucose monitoring software and systems.
  • Create verification and validation test plans, test reports, and traceability matrices, and review them with relevant stakeholders.
  • Record and track issues in the bug-tracking system.
  • Analyze failures and collaborate with development teams to investigate root causes.
  • Contribute to release-process improvements.
Desired Qualifications
  • Experience in the medical-device industry and with the Food and Drug Administration design-control process.
  • Knowledge of Google Cloud Platform with Airflow, Dataflow, and BigQuery.
  • Knowledge of distributed event-streaming platforms such as Kafka.
  • Experience with performance testing.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 13% to $1.31 billion; guidance reached $5.25 billion.
  • Gross margin hit 64.1% in Q2 2026, driven by manufacturing efficiencies.
  • Dexcom repurchased $600 million shares in Q2 2026, signaling strong cash generation.

What critics are saying

  • A September 2025 securities-fraud case alleges unauthorized G6 and G7 design changes.
  • Abbott’s FreeStyle Libre undercuts Dexcom on price, channel leverage, and wear-time.
  • Ireland ramp-up creates hiring, training, and depreciation drag before output starts.

What makes Dexcom unique

  • Dexcom’s G7 15 Day won Health Canada authorization on July 13, 2026.
  • Dexcom secured coverage for over 7 million non-insulin patients across major US PBMs.
  • Dexcom pairs CGM hardware with CLARITY, Health2Sync, and Helose workflow integrations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
TechDay
Aug 24th, 2026
Dexcom, Health2Sync partner on diabetes care in Asia.

Dexcom, Health2Sync partner on diabetes care in Asia. Mon, 24th Aug 2026 (Today) Dexcom and Health2Sync have formed a partnership focused on diabetes care in Australia and Singapore, linking glucose monitoring with digital chronic disease management. The partnership aims to support more connected care for people living with diabetes and their healthcare providers in both markets. It also reflects a broader push to expand digital health tools across Asia-Pacific. Health2Sync operates a digital chronic disease management platform that supports about 1.7 million users across the region. The company has built a presence in several Asian markets by offering tools that help people with diabetes and healthcare teams manage long-term care through digital services. Dexcom is known for its continuous glucose monitoring systems, which track glucose levels for people living with diabetes. The tie-up with Health2Sync reflects growing demand for connected healthcare technologies that support care coordination, simplify clinical workflows and enable more tailored approaches to chronic disease management. Regional push The deal gives Dexcom another partnership in Asia-Pacific as digital health companies seek to integrate monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both exploring greater use of remote monitoring and data-driven management for chronic conditions. Diabetes remains a major long-term health issue across the region, driving demand for systems that connect patient data with clinical decision-making. Companies in the sector have increasingly focused on linking devices, apps and care teams rather than offering standalone products. Health2Sync's scale in the region may give Dexcom access to a wider digital care network, while Dexcom's monitoring products add a stream of glucose data that can be incorporated into patient management. The companies have not disclosed commercial terms or product integration details. The announcement did not specify which Dexcom products or Health2Sync services would be included first in Australia and Singapore. It also did not say when any integrated offering would become available to users or healthcare providers. Company comments Both companies framed the partnership around a shared view that diabetes care can benefit from more connected management models. They said the arrangement is intended to help healthcare professionals and people living with diabetes access smarter, more connected ways to manage the condition. No financial details were released. The companies also did not outline any regulatory steps, local distribution arrangements or clinical partnerships tied to the agreement. More information is expected later. For now, the main disclosed fact is that Dexcom and Health2Sync are aligning their diabetes-related offerings across Australia and Singapore.

Ticker Report
Aug 21st, 2026
Silvant Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000. Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new […]

Yahoo Finance
Aug 12th, 2026
DexCom rallies 52.5% in three months as margins expand and earnings beat estimates

DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.

Yahoo Finance
Jul 31st, 2026
DexCom secures coverage for 7M patients, raises growth guidance after Q2 2026 results

DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.

Yahoo Finance
Jul 31st, 2026
DexCom's Q2 revenue climbs 13% to $1.31B, raises full-year guidance to $5.25B

DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.

INACTIVE